-
XW09 Nose
-
XW090 Open
-
XW0900 Brexanolone
-
XW0900 Spesolimab Monoclonal Antibody
-
XW0901 Daratumumab and Hyaluronidase-fihj
-
XW0901 Eladocagene exuparvovec
-
XW0902 Bromelain-enriched Proteolytic Enzyme
-
XW0902 Nerinitide
-
XW0903 Durvalumab Antineoplastic
-
XW0903 Maribavir Anti-infective
-
XW0904 Teclistamab Antineoplastic
-
XW0905 Mosunetuzumab Antineoplastic
-
XW0905 Narsoplimab Monoclonal Antibody
-
XW0906 Afamitresgene Autoleucel Immunotherapy
-
XW0906 Lefamulin Anti-infective
-
XW0906 Terlipressin
-
XW0907 Coagulation Factor Xa, Inactivated
-
XW0907 Tabelecleucel Immunotherapy
-
XW0907 Trilaciclib
-
XW0908 Lurbinectedin
-
XW0908 Mineral-based Topical Hemostatic Agent
-
XW0908 Treosulfan
-
XW0908 Uridine Triacetate
-
XW0909 Ceftolozane/Tazobactam Anti-infective
-
XW0909 Inebilizumab-cdon
-
XW0909 Satralizumab-mwge
-
XW090A Cefiderocol Anti-infective
-
XW090A Ciltacabtagene Autoleucel
-
XW090B Amivantamab Monoclonal Antibody
-
XW090B Cytarabine and Daunorubicin Liposome Antineoplastic
-
XW090B Omadacycline Anti-infective
-
XW090C Eculizumab
-
XW090C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
-
XW090D Atezolizumab Antineoplastic
-
XW090D Engineered Allogeneic Thymus Tissue
-
XW090E Etesevimab Monoclonal Antibody
-
XW090E Remdesivir Anti-infective
-
XW090F Bamlanivimab Monoclonal Antibody
-
XW090F Other New Technology Therapeutic Substance
-
XW090G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
-
XW090G Plazomicin Anti-infective
-
XW090G REGN-COV2 Monoclonal Antibody
-
XW090G Sarilumab
-
XW090H Axicabtagene Ciloleucel Immunotherapy
-
XW090H Other New Technology Monoclonal Antibody
-
XW090H Synthetic Human Angiotensin II
-
XW090H Tocilizumab
-
XW090J Apalutamide Antineoplastic
-
XW090J Tisagenlecleucel Immunotherapy
-
XW090K Fosfomycin Anti-infective
-
XW090K Idecabtagene Vicleucel Immunotherapy
-
XW090K Leronlimab Monoclonal Antibody
-
XW090L CD24Fc Immunomodulator
-
XW090L Erdafitinib Antineoplastic
-
XW090L Lifileucel Immunotherapy
-
XW090M Baricitinib
-
XW090M Brexucabtagene Autoleucel Immunotherapy
-
XW090M Esketamine Hydrochloride
-
XW090N Lisocabtagene Maraleucel Immunotherapy
-
XW090N Meropenem-vaborbactam Anti-infective
-
XW090P Antibiotic-eluting Bone Void Filler
-
XW090Q Tagraxofusp-erzs Antineoplastic
-
XW090R Fostamatinib
-
XW090R Venetoclax Antineoplastic
-
XW090S COVID-19 Vaccine Dose 1
-
XW090S Iobenguane I-131 Antineoplastic
-
XW090T COVID-19 Vaccine Dose 2
-
XW090T Ruxolitinib
-
XW090U COVID-19 Vaccine
-
XW090U Imipenem-cilastatin-relebactam Anti-infective
-
XW090V COVID-19 Vaccine Dose 3
-
XW090V Gilteritinib Antineoplastic
-
XW090W Caplacizumab
-
XW090W COVID-19 Vaccine Booster
-
XW090X Broad Consortium Microbiota-based Live Biotherapeutic Suspension
-
XW090X Tixagevimab and Cilgavimab Monoclonal Antibody
-
XW090Y Other New Technology Monoclonal Antibody
-
-
XW093 Percutaneous
-
XW0930 Brexanolone
-
XW0930 Spesolimab Monoclonal Antibody
-
XW0931 Daratumumab and Hyaluronidase-fihj
-
XW0931 Eladocagene exuparvovec
-
XW0932 Bromelain-enriched Proteolytic Enzyme
-
XW0932 Nerinitide
-
XW0933 Durvalumab Antineoplastic
-
XW0933 Maribavir Anti-infective
-
XW0934 Teclistamab Antineoplastic
-
XW0935 Mosunetuzumab Antineoplastic
-
XW0935 Narsoplimab Monoclonal Antibody
-
XW0936 Afamitresgene Autoleucel Immunotherapy
-
XW0936 Lefamulin Anti-infective
-
XW0936 Terlipressin
-
XW0937 Coagulation Factor Xa, Inactivated
-
XW0937 Tabelecleucel Immunotherapy
-
XW0937 Trilaciclib
-
XW0938 Lurbinectedin
-
XW0938 Mineral-based Topical Hemostatic Agent
-
XW0938 Treosulfan
-
XW0938 Uridine Triacetate
-
XW0939 Ceftolozane/Tazobactam Anti-infective
-
XW0939 Inebilizumab-cdon
-
XW0939 Satralizumab-mwge
-
XW093A Cefiderocol Anti-infective
-
XW093A Ciltacabtagene Autoleucel
-
XW093B Amivantamab Monoclonal Antibody
-
XW093B Cytarabine and Daunorubicin Liposome Antineoplastic
-
XW093B Omadacycline Anti-infective
-
XW093C Eculizumab
-
XW093C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
-
XW093D Atezolizumab Antineoplastic
-
XW093D Engineered Allogeneic Thymus Tissue
-
XW093E Etesevimab Monoclonal Antibody
-
XW093E Remdesivir Anti-infective
-
XW093F Bamlanivimab Monoclonal Antibody
-
XW093F Other New Technology Therapeutic Substance
-
XW093G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
-
XW093G Plazomicin Anti-infective
-
XW093G REGN-COV2 Monoclonal Antibody
-
XW093G Sarilumab
-
XW093H Axicabtagene Ciloleucel Immunotherapy
-
XW093H Other New Technology Monoclonal Antibody
-
XW093H Synthetic Human Angiotensin II
-
XW093H Tocilizumab
-
XW093J Apalutamide Antineoplastic
-
XW093J Tisagenlecleucel Immunotherapy
-
XW093K Fosfomycin Anti-infective
-
XW093K Idecabtagene Vicleucel Immunotherapy
-
XW093K Leronlimab Monoclonal Antibody
-
XW093L CD24Fc Immunomodulator
-
XW093L Erdafitinib Antineoplastic
-
XW093L Lifileucel Immunotherapy
-
XW093M Baricitinib
-
XW093M Brexucabtagene Autoleucel Immunotherapy
-
XW093M Esketamine Hydrochloride
-
XW093N Lisocabtagene Maraleucel Immunotherapy
-
XW093N Meropenem-vaborbactam Anti-infective
-
XW093P Antibiotic-eluting Bone Void Filler
-
XW093Q Tagraxofusp-erzs Antineoplastic
-
XW093R Fostamatinib
-
XW093R Venetoclax Antineoplastic
-
XW093S COVID-19 Vaccine Dose 1
-
XW093S Iobenguane I-131 Antineoplastic
-
XW093T COVID-19 Vaccine Dose 2
-
XW093T Ruxolitinib
-
XW093U COVID-19 Vaccine
-
XW093U Imipenem-cilastatin-relebactam Anti-infective
-
XW093V COVID-19 Vaccine Dose 3
-
XW093V Gilteritinib Antineoplastic
-
XW093W Caplacizumab
-
XW093W COVID-19 Vaccine Booster
-
XW093X Broad Consortium Microbiota-based Live Biotherapeutic Suspension
-
XW093X Tixagevimab and Cilgavimab Monoclonal Antibody
-
XW093Y Other New Technology Monoclonal Antibody
-
-
XW097 Via Natural or Artificial Opening
-
XW0970 Brexanolone
-
XW0970 Spesolimab Monoclonal Antibody
-
XW0971 Daratumumab and Hyaluronidase-fihj
-
XW0971 Eladocagene exuparvovec
-
XW0972 Bromelain-enriched Proteolytic Enzyme
-
XW0972 Nerinitide
-
XW0973 Durvalumab Antineoplastic
-
XW0973 Maribavir Anti-infective
-
XW0974 Teclistamab Antineoplastic
-
XW0975 Mosunetuzumab Antineoplastic
-
XW0975 Narsoplimab Monoclonal Antibody
-
XW0976 Afamitresgene Autoleucel Immunotherapy
-
XW0976 Lefamulin Anti-infective
-
XW0976 Terlipressin
-
XW0977 Coagulation Factor Xa, Inactivated
-
XW0977 Tabelecleucel Immunotherapy
-
XW0977 Trilaciclib
-
XW0978 Lurbinectedin
-
XW0978 Mineral-based Topical Hemostatic Agent
-
XW0978 Treosulfan
-
XW0978 Uridine Triacetate
-
XW0979 Ceftolozane/Tazobactam Anti-infective
-
XW0979 Inebilizumab-cdon
-
XW0979 Satralizumab-mwge
-
XW097A Cefiderocol Anti-infective
-
XW097A Ciltacabtagene Autoleucel
-
XW097B Amivantamab Monoclonal Antibody
-
XW097B Cytarabine and Daunorubicin Liposome Antineoplastic
-
XW097B Omadacycline Anti-infective
-
XW097C Eculizumab
-
XW097C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
-
XW097D Atezolizumab Antineoplastic
-
XW097D Engineered Allogeneic Thymus Tissue
-
XW097E Etesevimab Monoclonal Antibody
-
XW097E Remdesivir Anti-infective
-
XW097F Bamlanivimab Monoclonal Antibody
-
XW097F Other New Technology Therapeutic Substance
-
XW097G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
-
XW097G Plazomicin Anti-infective
-
XW097G REGN-COV2 Monoclonal Antibody
-
XW097G Sarilumab
-
XW097H Axicabtagene Ciloleucel Immunotherapy
-
XW097H Other New Technology Monoclonal Antibody
-
XW097H Synthetic Human Angiotensin II
-
XW097H Tocilizumab
-
XW097J Apalutamide Antineoplastic
-
XW097J Tisagenlecleucel Immunotherapy
-
XW097K Fosfomycin Anti-infective
-
XW097K Idecabtagene Vicleucel Immunotherapy
-
XW097K Leronlimab Monoclonal Antibody
-
XW097L CD24Fc Immunomodulator
-
XW097L Erdafitinib Antineoplastic
-
XW097L Lifileucel Immunotherapy
-
XW097M Baricitinib
-
XW097M5Introduction of Esketamine Hydrochloride into Nose, Via Natural or Artificial Opening, New Technology Group 5
-
-
XW097M Brexucabtagene Autoleucel Immunotherapy
-
XW097M5Introduction of Esketamine Hydrochloride into Nose, Via Natural or Artificial Opening, New Technology Group 5
-
-
XW097M Esketamine Hydrochloride
-
XW097M5Introduction of Esketamine Hydrochloride into Nose, Via Natural or Artificial Opening, New Technology Group 5
-
-
XW097N Lisocabtagene Maraleucel Immunotherapy
-
XW097N Meropenem-vaborbactam Anti-infective
-
XW097P Antibiotic-eluting Bone Void Filler
-
XW097Q Tagraxofusp-erzs Antineoplastic
-
XW097R Fostamatinib
-
XW097R Venetoclax Antineoplastic
-
XW097S COVID-19 Vaccine Dose 1
-
XW097S Iobenguane I-131 Antineoplastic
-
XW097T COVID-19 Vaccine Dose 2
-
XW097T Ruxolitinib
-
XW097U COVID-19 Vaccine
-
XW097U Imipenem-cilastatin-relebactam Anti-infective
-
XW097V COVID-19 Vaccine Dose 3
-
XW097V Gilteritinib Antineoplastic
-
XW097W Caplacizumab
-
XW097W COVID-19 Vaccine Booster
-
XW097X Broad Consortium Microbiota-based Live Biotherapeutic Suspension
-
XW097X Tixagevimab and Cilgavimab Monoclonal Antibody
-
XW097Y Other New Technology Monoclonal Antibody
-
-
XW098 Via Natural or Artificial Opening Endoscopic
-
XW0980 Brexanolone
-
XW0980 Spesolimab Monoclonal Antibody
-
XW0981 Daratumumab and Hyaluronidase-fihj
-
XW0981 Eladocagene exuparvovec
-
XW0982 Bromelain-enriched Proteolytic Enzyme
-
XW0982 Nerinitide
-
XW0983 Durvalumab Antineoplastic
-
XW0983 Maribavir Anti-infective
-
XW0984 Teclistamab Antineoplastic
-
XW0985 Mosunetuzumab Antineoplastic
-
XW0985 Narsoplimab Monoclonal Antibody
-
XW0986 Afamitresgene Autoleucel Immunotherapy
-
XW0986 Lefamulin Anti-infective
-
XW0986 Terlipressin
-
XW0987 Coagulation Factor Xa, Inactivated
-
XW0987 Tabelecleucel Immunotherapy
-
XW0987 Trilaciclib
-
XW0988 Lurbinectedin
-
XW0988 Mineral-based Topical Hemostatic Agent
-
XW0988 Treosulfan
-
XW0988 Uridine Triacetate
-
XW0989 Ceftolozane/Tazobactam Anti-infective
-
XW0989 Inebilizumab-cdon
-
XW0989 Satralizumab-mwge
-
XW098A Cefiderocol Anti-infective
-
XW098A Ciltacabtagene Autoleucel
-
XW098B Amivantamab Monoclonal Antibody
-
XW098B Cytarabine and Daunorubicin Liposome Antineoplastic
-
XW098B Omadacycline Anti-infective
-
XW098C Eculizumab
-
XW098C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
-
XW098D Atezolizumab Antineoplastic
-
XW098D Engineered Allogeneic Thymus Tissue
-
XW098E Etesevimab Monoclonal Antibody
-
XW098E Remdesivir Anti-infective
-
XW098F Bamlanivimab Monoclonal Antibody
-
XW098F Other New Technology Therapeutic Substance
-
XW098G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
-
XW098G Plazomicin Anti-infective
-
XW098G REGN-COV2 Monoclonal Antibody
-
XW098G Sarilumab
-
XW098H Axicabtagene Ciloleucel Immunotherapy
-
XW098H Other New Technology Monoclonal Antibody
-
XW098H Synthetic Human Angiotensin II
-
XW098H Tocilizumab
-
XW098J Apalutamide Antineoplastic
-
XW098J Tisagenlecleucel Immunotherapy
-
XW098K Fosfomycin Anti-infective
-
XW098K Idecabtagene Vicleucel Immunotherapy
-
XW098K Leronlimab Monoclonal Antibody
-
XW098L CD24Fc Immunomodulator
-
XW098L Erdafitinib Antineoplastic
-
XW098L Lifileucel Immunotherapy
-
XW098M Baricitinib
-
XW098M Brexucabtagene Autoleucel Immunotherapy
-
XW098M Esketamine Hydrochloride
-
XW098N Lisocabtagene Maraleucel Immunotherapy
-
XW098N Meropenem-vaborbactam Anti-infective
-
XW098P Antibiotic-eluting Bone Void Filler
-
XW098Q Tagraxofusp-erzs Antineoplastic
-
XW098R Fostamatinib
-
XW098R Venetoclax Antineoplastic
-
XW098S COVID-19 Vaccine Dose 1
-
XW098S Iobenguane I-131 Antineoplastic
-
XW098T COVID-19 Vaccine Dose 2
-
XW098T Ruxolitinib
-
XW098U COVID-19 Vaccine
-
XW098U Imipenem-cilastatin-relebactam Anti-infective
-
XW098V COVID-19 Vaccine Dose 3
-
XW098V Gilteritinib Antineoplastic
-
XW098W Caplacizumab
-
XW098W COVID-19 Vaccine Booster
-
XW098X Broad Consortium Microbiota-based Live Biotherapeutic Suspension
-
XW098X Tixagevimab and Cilgavimab Monoclonal Antibody
-
XW098Y Other New Technology Monoclonal Antibody
-
-
XW09X External
-
XW09X0 Brexanolone
-
XW09X0 Spesolimab Monoclonal Antibody
-
XW09X1 Daratumumab and Hyaluronidase-fihj
-
XW09X1 Eladocagene exuparvovec
-
XW09X2 Bromelain-enriched Proteolytic Enzyme
-
XW09X2 Nerinitide
-
XW09X3 Durvalumab Antineoplastic
-
XW09X3 Maribavir Anti-infective
-
XW09X4 Teclistamab Antineoplastic
-
XW09X5 Mosunetuzumab Antineoplastic
-
XW09X5 Narsoplimab Monoclonal Antibody
-
XW09X6 Afamitresgene Autoleucel Immunotherapy
-
XW09X6 Lefamulin Anti-infective
-
XW09X6 Terlipressin
-
XW09X7 Coagulation Factor Xa, Inactivated
-
XW09X7 Tabelecleucel Immunotherapy
-
XW09X7 Trilaciclib
-
XW09X8 Lurbinectedin
-
XW09X8 Mineral-based Topical Hemostatic Agent
-
XW09X8 Treosulfan
-
XW09X8 Uridine Triacetate
-
XW09X9 Ceftolozane/Tazobactam Anti-infective
-
XW09X9 Inebilizumab-cdon
-
XW09X9 Satralizumab-mwge
-
XW09XA Cefiderocol Anti-infective
-
XW09XA Ciltacabtagene Autoleucel
-
XW09XB Amivantamab Monoclonal Antibody
-
XW09XB Cytarabine and Daunorubicin Liposome Antineoplastic
-
XW09XB Omadacycline Anti-infective
-
XW09XC Eculizumab
-
XW09XC Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
-
XW09XD Atezolizumab Antineoplastic
-
XW09XD Engineered Allogeneic Thymus Tissue
-
XW09XE Etesevimab Monoclonal Antibody
-
XW09XE Remdesivir Anti-infective
-
XW09XF Bamlanivimab Monoclonal Antibody
-
XW09XF Other New Technology Therapeutic Substance
-
XW09XG Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
-
XW09XG Plazomicin Anti-infective
-
XW09XG REGN-COV2 Monoclonal Antibody
-
XW09XG Sarilumab
-
XW09XH Axicabtagene Ciloleucel Immunotherapy
-
XW09XH Other New Technology Monoclonal Antibody
-
XW09XH Synthetic Human Angiotensin II
-
XW09XH Tocilizumab
-
XW09XJ Apalutamide Antineoplastic
-
XW09XJ Tisagenlecleucel Immunotherapy
-
XW09XK Fosfomycin Anti-infective
-
XW09XK Idecabtagene Vicleucel Immunotherapy
-
XW09XK Leronlimab Monoclonal Antibody
-
XW09XL CD24Fc Immunomodulator
-
XW09XL Erdafitinib Antineoplastic
-
XW09XL Lifileucel Immunotherapy
-
XW09XM Baricitinib
-
XW09XM Brexucabtagene Autoleucel Immunotherapy
-
XW09XM Esketamine Hydrochloride
-
XW09XN Lisocabtagene Maraleucel Immunotherapy
-
XW09XN Meropenem-vaborbactam Anti-infective
-
XW09XP Antibiotic-eluting Bone Void Filler
-
XW09XQ Tagraxofusp-erzs Antineoplastic
-
XW09XR Fostamatinib
-
XW09XR Venetoclax Antineoplastic
-
XW09XS COVID-19 Vaccine Dose 1
-
XW09XS Iobenguane I-131 Antineoplastic
-
XW09XT COVID-19 Vaccine Dose 2
-
XW09XT Ruxolitinib
-
XW09XU COVID-19 Vaccine
-
XW09XU Imipenem-cilastatin-relebactam Anti-infective
-
XW09XV COVID-19 Vaccine Dose 3
-
XW09XV Gilteritinib Antineoplastic
-
XW09XW Caplacizumab
-
XW09XW COVID-19 Vaccine Booster
-
XW09XX Broad Consortium Microbiota-based Live Biotherapeutic Suspension
-
XW09XX Tixagevimab and Cilgavimab Monoclonal Antibody
-
XW09XY Other New Technology Monoclonal Antibody
-
-